ReviewCurrent osteoporosis reports2017
Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.
Review in Current osteoporosis reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling.Journal of periodontal research · 2026Review
- Article
- Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer.Molecules (Basel, Switzerland) · 2023Review
- Preventing osteolytic lesions and osteomyelitis in multiple myeloma.Journal of bone oncology · 2022Review
- The osteocyte as a signaling cell.Physiological reviews · 2022Review
- Osteocytes and Cancer.Current osteoporosis reports · 2021Review
- Bone Metastatic Breast Cancer: Advances in Cell Signaling and Autophagy Related Mechanisms.Cancers · 2021Review
- BMP antagonists in tissue development and disease.Matrix biology plus · 2021Review
- Emerging roles for myeloid immune cells in bone metastasis.Cancer metastasis reviews · 2021Review
- Management of Myeloma Bone Lesions.International journal of molecular sciences · 2021Review
- An eight-mRNA signature outperforms the lncRNA-based signature in predicting prognosis of patients with glioblastoma.BMC medical genetics · 2020Article
- Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.Current osteoporosis reports · 2020Review
- Osteocytes and Bone Metastasis.Frontiers in endocrinology · 2020Review
- Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.Frontiers in endocrinology · 2020Article
- The Emerging Role of Osteocytes in Cancer in Bone.JBMR plus · 2019Review
- Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.Pharmaceutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review provides a summary of the current knowledge on Sost/sclerostin in cancers targeting the bone, discusses novel observations regarding its potential as a therapeutic approach to treat cancer-induced bone loss, and proposes future research needed to fully understand the potential of therapeutic approaches that modulate sclerostin function. RECENT
findingsAccumulating evidence shows that sclerostin expression is dysregulated in a number of cancers that target the bone. Further, new findings demonstrate that pharmacological inhibition of sclerostin in preclinical models of multiple myeloma results in a robust prevention of bone loss and preservation of bone strength, without apparent effects on tumor growth. These data raise the possibility of targeting sclerostin for the treatment of cancer patients with bone metastasis. Sclerostin is emerging as a valuable target to prevent the bone destruction that accompanies the growth of cancer cells in the bone. Further studies will focus on combining anti-sclerostin therapy with tumor-targeted agents to achieve both beneficial skeletal outcomes and inhibition of tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.